<h3><strong>How are PFAS regulations changing, and what role will ion chromatography play in the future of environmental testing?</strong></h3><p>In this episode, &nbsp;David interviews <strong>Jay Gandhi, PhD, </strong>Vertical Markets Manager at <strong>Metrohm USA</strong>, for an in-depth discussion on PFAS analysis, the rise of AOF (Adsorbable Organic Fluorine) testing, and the development of EPA 1621 and ISO 18127 standards.</p><p>With more than 30 years of experience in ion chromatography, Jay shares valuable perspective on how the field has evolved—from early applications and NASA water recovery projects to today’s challenges involving PFAS, TFA, and emerging contaminants.</p><h4><strong>Topics covered in this episode include:</strong></h4><ul><li>What PFAS are and why they matter</li><li>The difference between targeted PFAS methods and AOF analysis</li><li>How combustion ion chromatography works</li><li>Behind the scenes of EPA 1621 and ISO 18127 method development</li><li>Regulatory trends in water, textiles, and food packaging</li><li>TFA analysis using IC-MS and IC-MS/MS</li><li>The future of ion chromatography in environmental labs</li></ul><h3><strong>Video Transcription</strong></h3><p>For more than three decades, Jay Gandhi has worked with ion chromatography (IC), watching the technique expand from a specialized tool for water analysis into an analytical platform used across environmental testing, food and beverage analysis, semiconductor manufacturing, battery applications, and, increasingly, PFAS analysis.</p><p>In an interview for <i>Concentrating on Chromatography</i>, Gandhi discusses his introduction to IC during his work on a NASA Mars exploration project, the emergence of PFAS as a major analytical challenge, and why techniques such as adsorbable organic fluorine (AOF) determination and combustion ion chromatography (CIC) can provide information that targeted LC-MS analysis alone cannot deliver. He also examines the development of standardized methods, sample preparation challenges, and the future role of IC-MS and total fluorine approaches in PFAS monitoring.</p><h4><strong>From NASA to ion chromatography</strong></h4><p>Gandhi's introduction to ion chromatography came through his work as a principal scientist on a NASA Mars exploration project focused on water recovery under zero-gravity conditions. IC played an important role because it enabled researchers to establish the ionic balance of anions and cations in water.</p><p>The technology was used both to investigate micronutrients relevant to agricultural applications and to evaluate water purity for potential astronaut consumption. During approximately three years of this work, Gandhi gained extensive experience with ion chromatography. This ultimately led him deeper into IC instrumentation and, 24 years ago, to joining Metrohm.</p><p>At the beginning of his career, IC was strongly associated with relatively straightforward anion and cation analysis in water. The technique itself had been used for water analysis since the 1970s, but Gandhi has seen its application range expand dramatically.</p><p>Food and beverage testing and environmental analysis became important fields, supported by both direct and indirect detection strategies. More recently, IC has also found applications in areas such as the semiconductor industry and battery recycling.</p><p>In Gandhi's words, ion chromatography has effectively "bloomed" into numerous application areas.</p><h4><strong>PFAS changes the analytical challenge</strong></h4><p>PFAS represent a particularly important chapter in this development. These chemicals have been used for decades in numerous consumer and industrial products, including non-stick materials, firefighting foams, water-resistant textiles and other applications.</p><p>Gandhi recalls work on PFOA and PFOS using ion chromatography with conductivity detection as early as 2008. However, the achievable detection limits were insufficient for the extremely low concentrations that later became important in PFAS analysis.</p><p>A major turning point for him came in 2015, when he encountered research from Sweden using <strong>combustion ion chromatography to investigate total fluorine</strong>. Subsequent collaboration with researchers at Clarkson University and Harvard University, particularly on aqueous film-forming foam (AFFF), further demonstrated the importance of looking beyond individual targeted PFAS compounds.</p><h4><strong>Why targeted LC-MS does not tell the whole story</strong></h4><p>Targeted LC-MS is highly sensitive and selective and can provide detailed information about individual PFAS compounds. However, according to Gandhi, the number of possible PFAS structures in the environment is vastly greater than the number routinely included in targeted methods.</p><p>A targeted method may monitor dozens or perhaps around one hundred compounds, while the overall PFAS universe can include thousands of chemical structures. Consequently, targeted analysis may characterize only a small fraction of the total PFAS burden.</p><p>There are other practical considerations. LC-MS measurements can be affected by matrix-dependent ion suppression, while accurate quantification frequently relies on isotope-labelled internal standards. Such standards are available for only a limited number of compounds and can be expensive.</p><p>This is where measurements of total or adsorbable organic fluorine can provide complementary information. Rather than asking <i>which specific PFAS compounds are present?</i>, these approaches can help answer a broader question: <i>how much fluorine associated with this chemical space is present in the sample?</i></p><h4><strong>AOF as a complementary approach</strong></h4><p>Adsorbable organic fluorine analysis provides a different perspective from targeted LC-MS. In the workflow discussed by Gandhi, organic fluorine compounds are captured during sample preparation and subsequently measured using combustion ion chromatography.</p><p>The principle of CIC builds upon older total organic halogen analysis. The sample is combusted at temperatures above approximately 1,000 °C, breaking carbon-halogen bonds. In PFAS-related analysis, carbon-fluorine bonds are broken and the resulting fluoride is collected in an absorption solution.</p><p>Ion chromatography is then used to separate and quantify the fluoride.</p><p>Replacing older detection approaches with IC provides both sensitivity and selectivity for the halogens being measured. Effective combustion is critical: oxygen supports the combustion process, while a carrier gas transports the products into the absorption solution for subsequent IC analysis.</p><h4><strong>The challenge of inorganic fluoride</strong></h4><p>The broad response of CIC is simultaneously one of its strengths and one of its analytical challenges. Combustion does not distinguish fluorine originating from PFAS from fluorine present in inorganic compounds such as fluoride salts.</p><p>This becomes particularly important when analyzing water containing relatively high concentrations of inorganic fluoride while attempting to quantify organic fluorine at very low levels.</p><p>Sample preparation therefore has a critical role. Inorganic fluoride must be effectively separated from the fraction of interest, while materials used during sample preparation must themselves have sufficiently low fluoride backgrounds.</p><p>Contamination can come from unexpected sources. Gandhi points out that background fluoride may originate not only from reagents and sample preparation materials but potentially from the laboratory environment. Careful blank control, appropriate materials and rigorous evaluation of interferences are therefore essential when moving toward increasingly low detection limits.</p><h4><strong>From research method to international standardization</strong></h4><p>The development of standardized AOF methods illustrates the importance of collaboration between academia, industry, regulatory organizations and analytical laboratories.</p><p>Gandhi describes work that began in Europe around 2015 and subsequently progressed through German standardization activities, ISO development, ASTM-related collaboration and the U.S. EPA. The process eventually contributed to methods such as <strong>EPA Method 1621</strong>.</p><p>He emphasizes that this was not the work of a single scientist or organization. Developing a robust method required years of experiments, discussions and sometimes difficult technical debates among numerous stakeholders.</p><p>For Gandhi, the essential principle was that experimental evidence ultimately had to determine the outcome. Collaboration becomes possible when scientists focus on the data rather than the organizations they represent.</p><h4><strong>PFAS monitoring is moving beyond drinking water</strong></h4><p>Regulatory attention to PFAS is also expanding beyond drinking water. Gandhi describes a broader strategy that begins with reducing the manufacture and use of PFAS-containing materials and continues with removing existing contamination from the environment.</p><p>Wastewater represents an important part of this picture because PFAS can enter it from numerous sources. Historical contamination from landfills and contaminated sites can also migrate into groundwater and ultimately affect drinking-water supplies.</p><p>Consumer products are another area of increasing attention. Food packaging, disposable containers, automotive fabrics, outdoor clothing and water-repellent textiles have historically used fluorinated substances to provide properties such as grease, water or stain resistance.</p><p>Reducing PFAS use in such products could therefore gradually decrease the amount entering waste streams and the wider environment.</p><h4><strong>Screening first, regulation later?</strong></h4><p>Gandhi expects AOF to be particularly valuable as a <strong>screening tool</strong>, providing an estimate of broader fluorine contamination before laboratories proceed to more specific analyses.</p><p>Its importance becomes clear when AOF results are compared with targeted PFAS measurements. Gandhi reports that laboratories working with EPA Method 1621 have observed differences between targeted PFAS results and broader AOF measurements ranging from approximately <strong>300- to 4,000-fold in the total fluorine mass balance</strong>.</p><p>Such discrepancies suggest that targeted methods can leave a substantial portion of fluorine unexplained.</p><p>Rather than competing with LC-MS, AOF and CIC therefore provide complementary information. A broad screening method can reveal the magnitude of total contamination, while targeted mass spectrometry identifies and quantifies specific compounds of interest.</p><h4><strong>Where IC-MS fits into the PFAS toolbox</strong></h4><p>No single technique can cover the entire PFAS problem. Gandhi highlights very short-chain, highly polar fluorinated compounds as another analytical challenge.</p><p>Compounds such as trifluoroacetic acid (TFA) are highly water-soluble and may not be quantitatively retained by the carbon materials used for AOF sample preparation. Direct ion chromatography can provide an alternative route for separating such compounds from common inorganic anions.</p><p>Coupling IC with mass spectrometry adds another level of sensitivity and selectivity. Gandhi therefore sees <strong>IC-MS and IC-MS/MS</strong> as increasingly important tools for highly polar fluorinated compounds. Similar approaches can also be useful beyond PFAS, including the determination of polar pesticides such as glyphosate and glufosinate.</p><h4><strong>Toward lower detection limits and more complete PFAS analysis</strong></h4><p>For Gandhi, current standardized methods represent a beginning rather than an endpoint. Improvements in instrumentation and particularly sample preparation could push total fluorine analysis to substantially lower concentrations.</p><p>He notes that current combustion IC configurations can reach approximately <strong>0.5 ppb</strong>, or 500 parts per trillion, and believes that improvements in sample volume, preparation procedures and mitigation of inorganic fluoride backgrounds could eventually move detection below 100 ppt and potentially toward 50 ppt.</p><p>Extractable organic fluorine workflows could provide another bridge between broad fluorine screening and targeted LC-MS methods. Combining improved extraction with CIC could allow samples to be screened for organic fluorine before more detailed compound-specific characterization.</p><p>The broader message from Gandhi's career is that PFAS analysis is unlikely to be solved by a single analytical technique. <strong>Targeted LC-MS provides compound-specific sensitivity and selectivity; AOF and combustion IC reveal a broader fluorine picture; and IC-MS can address highly polar compounds that are difficult to capture using conventional workflows.</strong> Used together, these techniques can provide laboratories with a much more complete understanding of PFAS contamination than any one approach alone.</p><blockquote><p><strong>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</strong></p></blockquote><blockquote><h4><strong>Concentrating on Chromatography Podcast</strong></h4><p>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!</p><p>You can find <strong>Concentrating on Chromatography Podcast </strong>in podcast apps:</p><ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL"><strong>Spotify</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185"><strong>Apple podcast</strong></a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography"><strong>podscan</strong></a></li></ul><p>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos"><strong>YouTube channel</strong></a></p></blockquote>

The Future of Ion Chromatography | PFAS Testing, EPA 1621 & AOF Explained

<p><strong>In late February 2025, a train carrying benzene derailed in Hustopeče nad Bečvou, and within hours, a race was on to save the groundwater and surface water. One of the most toxic industrial substances began seeping into the gravel-sand subsoil. While fieldwork was underway to prevent the spread of contamination, decisions were already being made in the CXI TUL laboratories regarding how to subsequently clean up the contaminated rock environment.</strong></p><p>The accident ranks among the <strong>most serious environmental incidents in the Czech Republic in recent years</strong>. After a tanker train derailed, hundreds of<strong> metric tons of benzene leaked</strong>; due to the highly permeable geological subsoil, it quickly seeped into deeper soil layers and into the groundwater. The combination of the substance’s high toxicity and local conditions complicated both the emergency response and the subsequent remediation. The key was to stop further spread, determine the extent of the contamination, and establish a remediation strategy for the entire site.</p><p>It was at this stage that CXI TUL became involved in the solution. At the request of the renowned remediation company DEKONTA, a.s., a team led by <strong>RNDr. Jan Němeček, Ph.D.</strong>, began testing the feasibility of the<strong> in situ chemical oxidation (ISCO) method</strong>. This technology is designed to<strong> break down benzene directly within the rock matrix</strong>, without the need for extensive excavation of contaminated soil or the pumping out of large volumes of groundwater. The goal was simple: to find a method that would work quickly, safely, and under the actual conditions of the affected site.</p><h4><strong>Benzene Remediation: Technically Simple, Complicated in Practice</strong></h4><p>Benzene is a highly toxic and carcinogenic substance that rapidly penetrates into groundwater in permeable subsoil, where it dissolves and spreads further as the water flows toward surface water bodies. Benzene also binds to rock particles and migrates in the form of vapors into overlying unconsolidated layers.</p><p>Scientists in Liberec therefore tested <i>in situ </i>chemical oxidation (ISCO) technology under laboratory conditions. The goal was to find an oxidant capable of breaking down benzene directly underground into less hazardous substances.</p><p>The tests evaluated two main options:<strong> activated hydrogen peroxide and sodium peroxodisulfate</strong>. Both substances removed up to<strong> 99.99% of the benzene</strong>, but there was a difference in their kinetics and impacts on the natural environment. Activated hydrogen peroxide achieved nearly complete degradation of the contaminant within a single day. Activated sodium peroxodisulfate was slower and also significantly altered the chemistry of the water; it acidified the environment and increased the sulfate content in the water, which poses an additional environmental burden.</p><p>For field applications, the researchers therefore unequivocally recommended <strong>activated hydrogen peroxide</strong>.</p><h4><strong>Dosage Matters</strong></h4><p>It was not just the oxidant’s effectiveness that was key. It was equally important to determine how the chemical reaction would behave in a real geological environment. The team of scientists therefore also analyzed what is known as <strong>soil oxidant consumption (SOD)</strong>. It turned out that a significant portion of the oxidizing agent does not react solely with benzene but is also consumed to a significant extent by the rock environment itself, particularly by natural organic substances present in the fine-grained fraction of the soil.</p><p>An oxidant consumption value was determined specifically for the local composition of the aquifers, which is essential for the correct dosing of chemicals in the field so that the remediation is not only effective but also economically viable and safe for surrounding ecosystems.</p><h4><strong>One Year After the Accident: Research Turns into Real-World Assistance</strong></h4><p>While the public often perceives university science as a distant world of laboratories and grant projects, it is precisely situations like this that demonstrate its practical impact. The results of the work by researchers at CXI TUL did not remain confined to academic studies but directly influenced decisions regarding the technology used to clean up one of the largest environmental accidents in recent years.</p>

Science on the Front Lines: Cleanup of a Benzene Spill

<p><strong>This study uses ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) lipidomics to characterize plasma lipid alterations associated with long-term aromatase inhibitor therapy in postmenopausal breast cancer patients. A total of 649 lipid species across 23 classes and subclasses were relatively quantified, revealing significant differences in phosphatidylcholines, sphingomyelins, ceramides, hexosylceramides, and other lipid groups.</strong></p><p>Multivariate analysis showed clear group separation, while a Naive Bayes model based on lipid-class profiles achieved an AUC of 0.79. The results indicate that aromatase inhibitor therapy is associated with systematic lipidomic changes linked to estrogen deprivation and sphingolipid metabolism, providing potential mechanistic insight into long-term metabolic effects of treatment.</p><blockquote><h4><strong>The original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926"><strong>Aromatase Inhibitor Therapy Is Associated with Distinct Plasma Lipidomic Profiles in Postmenopausal Breast Cancer Patients&nbsp;</strong></a></h4><div><span>Aleksandra Arsic, Ales Kvasnicka</span><a target="_blank" rel="noopener noreferrer" href="https://orcid.org/0000-0001-5973-316X"><span><img></span></a><span>, David Friedecky</span><a target="_blank" rel="noopener noreferrer" href="https://orcid.org/0000-0002-3448-9073"><span><img></span></a><span>, Nebojsa Ivanovic, Maja Milosevic</span><a target="_blank" rel="noopener noreferrer" href="https://orcid.org/0000-0002-0985-0728"><span><img></span></a><span> and Vesna Vucic</span></div><p>Int. J. Mol. Sci. <strong>2026</strong>, 27(4), 1926</p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.3390/ijms27041926">https://doi.org/10.3390/ijms27041926</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><p><strong>Selected sections from the article follow. Formats and hyperlinks were adapted from the original.</strong></p><div><div><p>Breast cancer (BRC) is the most common malignancy among women, with over 2.2 million new cases diagnosed globally in 2022 [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B1-ijms-27-01926">1</a>]. A substantial proportion of breast cancers are estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B2-ijms-27-01926">2</a>], necessitating multimodal treatment approaches, including surgery, chemotherapy, radiotherapy, and endocrine therapy. Aromatase inhibitors (AIs) represent the gold-standard adjuvant endocrine treatment for postmenopausal women, as they improve disease control and reduce the risk of distant metastasis by inhibiting peripheral aromatase activity [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B3-ijms-27-01926">3</a>]. This inhibition prevents the conversion of androgenic precursors into estrogens in peripheral tissues, resulting in a marked reduction in systemic estrogen levels. For postmenopausal women with ER+ and PR+ breast tumors, a five-year course of AI therapy, often extended beyond this duration, is recommended to reduce the risk of disease recurrence [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B4-ijms-27-01926">4</a>].</p><p>AIs decrease plasma and tissue concentrations of endogenous estrogens by inhibiting aromatase (cytochrome P450), the rate-limiting enzyme responsible for estrogen biosynthesis from testosterone and adrenal androgens [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B5-ijms-27-01926">5</a>]. Because estrogen plays a protective role in lipid metabolism, AI therapy is frequently associated with dyslipidemia. Increased levels of triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL) have been reported in patients receiving AIs [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B6-ijms-27-01926">6</a>], thereby increasing the risk of cardiovascular disease (CVD) in postmenopausal women with BRC [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B7-ijms-27-01926">7</a>].</p><p>Disturbances in lipid metabolism are recognized as a hallmark of cancer, leading to increasing interest in lipidomic profiling as a tool for characterizing tumor-associated metabolic alterations [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B8-ijms-27-01926">8</a>]. In recent years, clinical lipidomics studies have been conducted across multiple malignancies, including lung [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B9-ijms-27-01926">9</a>], pancreatic [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B10-ijms-27-01926">10</a>], renal cell carcinoma [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B11-ijms-27-01926">11</a>], colorectal [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B12-ijms-27-01926">12</a>], and BRC [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B13-ijms-27-01926">13</a>], highlighting cancer-specific lipidomic signatures and the growing relevance of lipid metabolism in oncology. Lipidomic reprogramming is now recognized as a defining feature of BRC. To date, elevated levels of phosphatidylcholine (PC 32:1), stearic acid, and ceramide (Cer 43:1), along with reduced levels of diacylglycerol (DG 34:2), have been reported in BRC patients compared with healthy women [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B14-ijms-27-01926">14</a>]. These lipid species, together with phosphatidylinositol (PI 16:0/16:1) and PI (18:0/20:4), have been proposed as potential biomarkers for BRC [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B14-ijms-27-01926">14</a>].</p><p>Despite these advances, there remains a paucity of studies investigating the lipidomic profiles in BRC patients in relation to endocrine therapy. The present cross-sectional study aims to address this gap by conducting mass spectrometry-based profiling of lipid classes and comparing profiles between postmenopausal BRC patients receiving AI therapy and another cohort assessed before this treatment. This approach aims to characterize associations between AI therapy status and plasma lipidomic patterns.</p><h4><strong>2. Results</strong></h4><h5><strong>2.3. Lipidomic Analysis</strong></h5><p>Plasma lipid profiling identified 649 lipids across 23 lipid classes and subclasses, covering the major structural families of the circulating lipidome, including neutral lipids (triacylglycerols, diacylglycerols, cholesteryl esters, and cholesterol), glycerophospholipids (phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylglycerols, phosphatidylserines, and their lysophospholipid counterparts), sphingolipids (sphingomyelins, ceramides, monohexosylceramides, and dihexosylceramides), and free fatty acids. In addition to diacyl phospholipids, the dataset included ether-linked and plasmalogen species (denoted as O- and P-), most prominently within PC, PE, and LPC and LPE classes. An overview of the plasma lipidome is shown as a global lipid network (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#fig_body_display_ijms-27-01926-f001">Figure 1</a>). To assess whether the observed lipid changes reflect coordinated remodeling rather than isolated signals, we performed Fisher’s combined probability test at the lipid-class level. This analysis revealed significant cumulative differences in several lipid classes, including Cer, LPC, ether/plasmalogen LPC, LPE, and SM (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#fig_body_display_ijms-27-01926-f001">Figure 1</a>), supporting systematic class-level alterations despite limited power at the single-species level.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Int_J_Mol_Sci_2026_27_4_1926_Figure_1_Global_lipid_network_analysis_of_plasma_lipidomic_differences_between_breast_cancer_patients_BRC_prior_to_initiation_of_the_aromatase_inhibitor_6f82827773.jpg" alt="Int. J. Mol. Sci. 2026, 27(4), 1926: Figure 1. Global lipid network analysis of plasma lipidomic differences between breast cancer patients (BRC) prior to initiation of the aromatase inhibitor (AI) therapy and patients receiving AI. Cytoscape-based network visualization illustrates lipid species grouped according to structural similarity and lipid class. Each node represents an individual lipid species, while edges indicate class-based relationships. Node size corresponds to the −log10 p-value from the Mann–Whitney U test, reflecting the statistical significance (−log p-Value &gt; 1.3) of differences between groups. Node color indicates the direction and magnitude of change, based on log2 fold change, with red representing higher abundance in AI-treated patients and blue representing higher abundance in patients before AI therapy. Major lipid classes, including glycerophospholipids (GPL), sphingolipids (SP), glycerolipids (GL), fatty acids (FA), and cholesteryl esters (CE), are shown to highlight coordinated class- and species-level lipidomic alterations. Fisher’s combined p-value for individual lipid classes is shown at the bottom (significant p-Value &lt; 0.05). " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Int_J_Mol_Sci_2026_27_4_1926_Figure_1_Global_lipid_network_analysis_of_plasma_lipidomic_differences_between_breast_cancer_patients_BRC_prior_to_initiation_of_the_aromatase_inhibitor_6f82827773.jpg 245w," sizes="100vw" width="1600" height="847"></p><h5><strong>2.4. Multivariate Analysis of Plasma Lipidomic Profiles</strong></h5><p>Principal component analysis (PCA) and partial least squares discriminant analysis (OPLS-DA) were applied to the lipidomic dataset to assess global variation and group separation between the BRC and AI groups (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#fig_body_display_ijms-27-01926-f002">Figure 2</a>). PCA was performed as an unsupervised analysis, including all samples and quality control (QC) samples. The first two principal components explained 37.9% (PC1) and 15.6% (PC2) of the total variance, accounting for 53.5% of the cumulative variance. QC samples clustered tightly near the center of the PCA score plot, indicating analytical stability and reproducibility of the LC–MS measurements. In the PCA score plot, samples from the BRC and AI groups showed partial overlap, with no complete separation observed along the first two principal components. To further evaluate group discrimination, a supervised OPLS-DA model was constructed using the same dataset. The OPLS-DA score plot demonstrated improved separation between the BRC and AI groups along the first latent variable, with group-specific clustering highlighted by confidence ellipses. Permutation testing confirmed that the supervised OPLS-DA model was not overfitted, with a negative Q<sup>2</sup> intercept (Q<sup>2</sup> = −0.55), indicating that permuted models lacked predictive ability compared with the original model (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#app1-ijms-27-01926">Supplementary Figure S1</a>). Together, these multivariate analyses indicate differences in lipidomic profiles between the BRC and AI groups, while also demonstrating acceptable analytical performance as evidenced by the clustering of QC samples.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Int_J_Mol_Sci_2026_27_4_1926_Figure_2_Multivariate_analysis_of_plasma_lipidomic_profiles_in_breast_cancer_patients_BRC_56f65f265b.jpg" alt="Int. J. Mol. Sci. 2026, 27(4), 1926: Figure 2. Multivariate analysis of plasma lipidomic profiles in breast cancer patients (BRC) prior to initiation of the aromatase inhibitor (AI) therapy and patients receiving AI. Principal component analysis (PCA) score plot (a) shows the distribution of plasma lipidomic profiles from patients before AI therapy (BRC, blue), patients receiving AI therapy (AI, red), and quality control samples (QC, gray). Orthogonal partial least squares–discriminant analysis (OPLS-DA) score plot (b) demonstrates improved separation between BRC and AI groups. The ellipse represents the 95% Hotelling’s T2 confidence interval. " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Int_J_Mol_Sci_2026_27_4_1926_Figure_2_Multivariate_analysis_of_plasma_lipidomic_profiles_in_breast_cancer_patients_BRC_56f65f265b.jpg 245w," sizes="100vw" width="1600" height="652"></p><h4><strong>4. Materials and Methods</strong></h4><h5><strong>4.5. Lipidomic Analysis</strong></h5><p>Chromatographic separation was performed using an ultra-high-performance liquid chromatography (UHPLC) <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=55&amp;search=ExionLC"><strong>ExionLC system</strong></a> (SCIEX, Framingham, MA, USA) coupled to a <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=55&amp;search=6500"><strong>QTRAP<sup>®</sup> 6500+ mass spectrometer </strong></a>(SCIEX, Framingham, MA, USA). Lipids were separated on an <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1953"><strong>ACQUITY Premier BEH C8 column</strong></a> (100 × 2.1 mm, 1.7 μm; Waters Corporation, Wilmslow, UK). The column temperature was kept at 55 °C, and the autosampler was set to 10 °C. The mobile phases consisted of solvent A (acetonitrile/water, 6:4, <span>v</span>/<span>v</span>, containing 10 mM ammonium acetate) and solvent B (isopropanol/acetonitrile, 9:1, <span>v</span>/<span>v</span>, containing 10 mM ammonium acetate), delivered at a flow rate of 0.4 mL/min. The total analytical run time was 20 min per sample. Data acquisition was carried out using Analyst software (version 1.6.2), and data processing and semiautomatic peak integration were performed with MultiQuant software (version 3.0; SCIEX, Framingham, MA, USA). Samples were analyzed in a randomized sequence with continuous monitoring of quality control samples. Raw peak areas were QC-normalized by LOESS [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B48-ijms-27-01926">48</a>] and IS-normalized by the corresponding IS class for each lipid.</p><h5><strong>4.6. Statistical Analysis</strong></h5><p>The data were processed using the Metabol package [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B48-ijms-27-01926">48</a>] in R program (v 3.6.3). Preprocessing of the data included locally estimated scatterplot smoothing (LOESS), Pareto scaling, filtering of analytes (coefficients of variation in the QC above 30%), mean centering, and the lnPQN normalization (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#app1-ijms-27-01926">Supplementary Table S1</a>) [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B49-ijms-27-01926">49</a>]. Univariate statistical analysis (based on the non-parametric non-paired Mann–Whitney U test (<span>p</span>-values shown as −log) together with the log2 fold-change in medians) was performed and visualized using GraphPad Prism (version 9.0, GraphPad Software, LLC, Boston, MA, USA). Data were also evaluated using multivariate statistical analysis, namely the principal component analysis (PCA) and orthogonal discriminant analysis by partial least squares (OPLS-DA) and validated by permutation using SIMCA software (version 18.0, Sartorius Umetrics, Umeå, Sweden). Benjamini–Hochberg correction was used for false discovery rate correction. Detected lipid species were mapped to standardized lipid classes and subclasses according to accepted lipidomics nomenclature, enabling consistent grouping of lipid species for downstream statistical, class-level, and network analyses. LipidOne 2.4 was further used to support lipid-centric data integration and visualization prior to multivariate and pathway-based analyses (such as heatmaps, ROC analyses using a Naive-Bayesian model and Logistic Regression model, and protein–protein interaction network based on lipidomics data) [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B50-ijms-27-01926">50</a>]. Lipid network visualization was performed using Cytoscape software (v 3.8.2) [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B51-ijms-27-01926">51</a>]. Differentially abundant lipid species were organized according to lipid class and structural similarity. Node size reflected the −log10 <span>p</span>-value from univariate analysis, while node color represented log2 fold change between groups. Calculation of Fisher’s combined probability test for assessing systematic lipid class-level differences was performed (<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#app1-ijms-27-01926">Supplementary Table S2</a>) and calculated following procedures described previously [<a target="_blank" rel="noopener noreferrer" href="https://www.mdpi.com/1422-0067/27/4/1926#B52-ijms-27-01926">52</a>].</p><h4><strong>5. Conclusions</strong></h4><p>In conclusion, our findings demonstrate significant alterations in lipid metabolism in BRC patients undergoing AI therapy, with pronounced changes in Cer, SM, DG, TG, PC, PI, and PE lipids and lipid classes. However, the precise mechanisms underlying the differences in lipid metabolism between patients before and during AI treatment remain to be fully elucidated. Future longitudinal studies with paired pre- and post-treatment samples from the same individuals leveraging comprehensive lipidomic profiling are needed to deepen our understanding of AI-induced metabolic alterations and to inform the development of targeted interventions aimed at mitigating adverse effects, ultimately improving long-term outcomes and quality of life for these patients.</p></div></div>

Aromatase Inhibitor Therapy Is Associated with Distinct Plasma Lipidomic Profiles in Postmenopausal Breast Cancer Patients

Article

Video

Scientists

Environment

Health

Scientific article

Interview

Science and research

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

The Institute for Nanomaterials, Advanced Technologies and Innovations of the Technical University of Liberec, also known as CXI TUL, was founded in 2009. Our mission is to support TUL's long-term vision of collaboration with industry and innovation.

CXI TUL

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Waters Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry

The Xevo® G2-XS QTof combines StepWaveTM ion optics with the XS Collision Cell, providing a significant increase in sensitivity with no reduction in selectivity.

<h4><strong>eXtreme Sensitivity, eXtraordinary Selectivity, eXceptional Solutions</strong></h4><div><p><strong>For the scientist who needs to identify, quantify and confirm the broadest range of compounds in the most complex and challenging samples.</strong></p><ul><li>Maximum robustness with no compromise in performance</li><li>Class-leading real-world quantitative sensitivity</li><li>Highest quality, most comprehensive qualitative information</li><li>Flexibility to adapt to changing needs</li><li>Accessible to experts and non-experts alike</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_1_b9f8dd32be/Waters-Xevo-G2-XS-QTof-Quadrupole-Time-of-Flight-Mass-Spectrometry-1.jpg" alt="Waters Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_1_b9f8dd32be/thumbnail_Waters-Xevo-G2-XS-QTof-Quadrupole-Time-of-Flight-Mass-Spectrometry-1.jpg 173w," sizes="100vw" width="1099" height="991"></p><h3><strong>Overview</strong></h3><div><h4><strong>Maximum robustness with no compromise in performance</strong></h4><p>The trend for increasing complexity of both samples and studies can result in difficulty obtaining high quality data for every component of interest while maintaining optimum performance throughout the analysis.</p><p>The <strong>Xevo® G2-XS QTof</strong> combines <strong>StepWave<sup>TM</sup> ion optics</strong> with the <strong>XS Collision Cell</strong>, providing a significant increase in sensitivity with no reduction in selectivity.&nbsp; During long analyses, critical hardware components stay clean for longer, so results are more reproducible and the laboratory stays productive.</p><p>Meaningful information is obtained for a greater number of components across a larger population of samples than ever before, giving a more complete picture for improved understanding and more confident decision making.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_437f84bacd.jpg" alt="Waters Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry: Maximum robustness with no compromise in performance." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_437f84bacd.jpg 224w," sizes="100vw" width="900" height="628"></p><div><h4><strong>Class-leading real-world quantitative sensitivity</strong></h4><p>In targeted quantitative analysis, the greatest challenge is to detect and quantify components of interest down to the lowest possible levels, often in the presence of interferences from complex matrix.&nbsp; Large variation in the concentrations of different components further adds to this challenge.</p><p>The <strong>Xevo G2-XS QTof</strong> combines sensitivity and selectivity with the mass accuracy, dynamic range and speed provided by <strong>QuanTofTM technology</strong> and the enhanced quantitative capability of <strong>Tof-MRM data acquisition</strong>.&nbsp; The end result is class-leading quantitative performance in real everyday laboratory conditions, demonstrated by limits of detection and quantification superior to anything achieved before with high resolution MS.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_2_d805c7aa49.jpg" alt="Waters Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry: Class-leading real-world quantitative sensitivity." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_2_d805c7aa49.jpg 245w," sizes="100vw" width="900" height="312"></p><div><h4><strong>Highest quality, most comprehensive qualitative information</strong></h4><p>In addition to accurate quantitative profiles, complete understanding of a sample requires detailed and comprehensive qualitative information.</p><p><strong>MS<sup>E</sup></strong> is a simple but powerful approach that delivers accurate mass precursor and fragment ion data for every detectable component, whether chromatographically resolved or not.&nbsp; This represents the ultimate in qualitative information, and because the approach is un-targeted, the data can be interrogated again later as scientific questions evolve.</p><p><strong>FastDDA</strong> is an automated, targeted data acquisition method that provides rapid, intelligent accurate mass MS/MS capability for confirmation of known compounds or characterization of unknowns, for situations where only true MS/MS data will suffice.</p><h4><strong>Flexibility to adapt to changing needs</strong></h4><div><p>The growing emphasis on efficiency and productivity in the laboratory demands analytical systems that are not only robust and reliable, but that also have the flexibility to accomplish a wide variety of tasks today, with future-proofing for the innovations of tomorrow.&nbsp;</p><p><strong>Waters’ Universal Ion Source Architecture</strong> enables the use of a single analytical platform for many different applications and molecule types, as well as providing the option to add new functionality as requirements and priorities change.&nbsp; All source options are designed to be quickly interchangeable and ready to use within minutes, maximizing versatility and minimizing downtime.</p><div><h3><strong>Accessible to experts and non-experts alike</strong></h3><p>Traditionally the ability to achieve and maintain optimum performance from such a powerful analytical system would require a level of knowledge and experience held only by expert users.</p><p>The <strong>Xevo G2-XS QTof</strong> features <strong>IntelliStartTM technology</strong>, an intuitive user interface that automates routine tasks and ensures reproducible data of the highest quality, ensuring the full capability of the system is accessible to all.</p><p><strong>IntelliStart enables essential functions to be carried out automatically:</strong></p><ul><li>MS resolution and calibration checks</li><li>Simple setup of diverse experiments</li><li>Scheduled LC-MS system checks</li><li>Continuous system monitoring</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_3_279cf35277.jpg" alt="Waters Xevo G2-XS QTof Quadrupole Time-of-Flight Mass Spectrometry: Accessible to experts and non-experts alike." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Xevo_G2_XS_Q_Tof_Quadrupole_Time_of_Flight_Mass_Spectrometry_3_279cf35277.jpg 136w," sizes="100vw" width="900" height="1038"></p></div></div></div></div></div></div>

Waters SELECT SERIES Cyclic IMS

The SELECT SERIES Cyclic IMS combines novel cyclic ion mobility separation with state-of-the-art, high performance, time-of-flight mass spectrometry.

<div><div id="title-c6692d35e8" data-locator="title-with-text"><h3><strong>Endless possibilities. Limitless research.</strong></h3></div></div><div><div id="text-ba9d3d94da" data-locator="text"><p><strong>Developed through focused collaboration, the SELECT SERIES Cyclic IMS combines novel cyclic ion mobility separation with state-of-the-art, high performance, time-of-flight mass spectrometry, enabling leading researchers to unlock the potential in scientific discovery.</strong></p><p>The SELECT SERIES Cyclic IMS enables selection of ions by both mass and mobility, a unique functionality of <strong>Cyclic Ion Mobility (cIM)</strong> that provides unparalleled flexibility and capabilities for research studies in both academia and industry. With ion mobility and mass spectrometry, you can separate by shape as well as&nbsp;<i>m/z</i>&nbsp;for separation of isomers, measure the <strong>Collisional Cross Section (CCS)</strong> of an ion, and achieve significantly cleaner mass spectral data.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_Cyclic_IMS_Novel_Cyclic_Ion_Mobility_c_IM_Technology_13abf6dd9b.jpg" alt="Waters SELECT SERIES Cyclic IMS: Novel Cyclic Ion Mobility (cIM) Technology." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_Cyclic_IMS_Novel_Cyclic_Ion_Mobility_c_IM_Technology_13abf6dd9b.jpg 234w," sizes="100vw" width="1024" height="682"></p><h3><strong>Overview</strong></h3><div data-locator="section-container-body"><div><div><div data-locator="layoutcontainer-"><div><div id="text-26eab4b89b" data-locator="text"><ul><li>Combine <strong>cyclic ion mobility (cIM) separation</strong> with <strong>ToF mass spectrometry</strong></li><li>Separate more than ever before with ultimate ion mobility resolution for complete confidence</li><li>Perform <strong>unique IMS<sup>n</sup> experiments</strong> for increased selectivity and advanced characterization</li><li>Enable <strong>pre-mobility mass selection</strong> and <strong>mobility selection of precursor and product ions</strong></li><li>Achieve increased experimental flexibility for solving complex problems with three distinct fragmentation regions</li></ul></div></div><div><div id="text-36ff553b5f" data-locator="text"><h3><strong>Recommended Use</strong></h3><p>For identifying and rapidly monitoring co-eluting, isomeric metabolites in chemical reactions</p><blockquote><p class="cke-user_style-important"><strong>Video: </strong><a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/watch?v=nauwVH0L91o"><strong>Waters SELECT SERIES Cyclic IMS</strong></a></p></blockquote><div><div id="text-8469d7776e" data-locator="text"><h3 data-locator="modal-title"><strong>Discover more with ultimate ion mobility resolution</strong></h3><p>The instrument design and control software enable a range of experiments, including acquisition of Tof data, Single pass ion mobility, and the ability to scale mobility resolution to match the complexity of a sample. Ion mobility resolution increases with the length of the mobility device and therefore with the number of passes.</p><figure class="image"><img style="aspect-ratio:1024/682;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_Cyclic_IMS_IMS_resolution_increases_with_the_number_of_passes_around_the_c_IM_device_121719dbe0.jpg" alt="Waters SELECT SERIES Cyclic IMS: IMS resolution increases with the number of passes around the cIM device. Demonstrated here by the separation of reverse sequence peptides SDGRG and GRGDS. The Arrival Time Distributions (ATDs) obtained after 100 passes around the device are inset." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_Cyclic_IMS_IMS_resolution_increases_with_the_number_of_passes_around_the_c_IM_device_121719dbe0.jpg 234w," sizes="100vw" width="1024" height="682"></figure><div><div id="text-bb2fb9f91c" data-locator="text"><h3 data-locator="modal-title"><strong>Unlock the potential in scientific discovery</strong></h3><p>The unique instrument design of the SELECT SERIES Cyclic IMS&nbsp;facilitates advanced ion mobility experiments like IMS<sup>n</sup>&nbsp;isolation. IMS<sup>n</sup>&nbsp;isolation&nbsp;extends the resolution of a specific mobility range,&nbsp;<i>e.g.,</i>&nbsp;ions of a specific species. Eject ions (without acquisition) outside of the desired mobility range, leaving the remaining species in the cIM to continue the separation process. This “trimming” approach can be undertaken numerous times and can be used, for example, to increase specificity of the selected ions or to prevent “wrap-around” in the cIM where high mobility ions catch up with low mobility ions in multi-pass experiments. Multiple cyclic sequences of different numbers of passes can be defined in one, multi-pass LC-MS method, increasing productivity by reducing the need for multiple injections of the same sample.</p></div></div><figure class="image"><img style="aspect-ratio:1024/578;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_Cyclic_IMS_Investigation_into_acyl_glucuronides_via_infusion_f3bf2c67e2.jpg" alt="Waters SELECT SERIES Cyclic IMS: Investigation into acyl glucuronides via infusion. Slicing enables further IMS separation of target metabolite (blue region) of interest and other ions can be ejected. Increasing the IMS resolution reveals an additional 4-O acyl. In collaboration with Imperial College London – Ian D. Wilson." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_Cyclic_IMS_Investigation_into_acyl_glucuronides_via_infusion_f3bf2c67e2.jpg 245w," sizes="100vw" width="1024" height="578"></figure><div><div id="text-78a4dc4d5e" data-locator="text"><h3 data-locator="modal-title"><strong>Undertake advanced structural characterization</strong></h3><p><strong>IMS<sup>n</sup>&nbsp;activation</strong>&nbsp;is ideal for <strong>advanced structural characterization</strong>. During mobility separation, excise a segment of the mobility separated species and send the ions to the pre array storage device. Unwanted ions are ejected, and the stored ions are then re-injected into the array under collision induced activation/dis-sociation conditions, as required, and subsequent mobility separation performed. The product ions can then be sent to the&nbsp;Tof<i>&nbsp;</i>for detection or can undergo further rounds of mobility selection providing the unique IMS<sup>n</sup>&nbsp;capability.</p></div></div><div><div id="text-079d02ceb8" data-locator="text"><h3 data-locator="modal-title"><strong>Imaging mass spectrometry with DESI XS and Cyclic IMS</strong></h3><p>The unique combination of&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?instrumentationItems=26&amp;mainauthorItems=5&amp;search=DESI+XS"><strong>DESI XS</strong></a><strong>&nbsp;</strong>with SELECT SERIES Cyclic IMS provides ultimate levels of specificity for <strong>MS imaging</strong> approaches. DESI XS produces a visual map of the spatial distribution of a wide range of analytes, for example small molecule drugs, metabolites, and lipids across the surface of a tissue sample, and the unique capabilities and modes of acquisition of Cyclic IMS enable comprehensive in-depth experiments to be performed.</p></div></div><div><div id="text-673d117887" data-locator="text"><h3 data-locator="modal-title"><strong>Increased sensitivity provides confidence in what you find</strong></h3><p>To complement the novel <strong>Cyclic Ion Mobility</strong> capability and for complete confidence in your data, the&nbsp;SELECT SERIES&nbsp;Cyclic IMS is equipped with the latest <strong>ToF technology</strong>. The XS transfer device maintains the fidelity of the ion mobility separation while simultaneously conditioning the ion beam for the absolute best time-of-flight performance. The new offset oa-Tof with dual gain detection system <strong>provides improved sensitivity, resolution &gt;100,000 (FWHM), reliable accurate exact mass measurements</strong> (low ppm), and <strong>improved dynamic range</strong>.</p><figure class="image"><img style="aspect-ratio:1024/682;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Mass_spectrum_highlighting_resolution_of_100_000_FWHM_on_the_7_charge_state_of_monomeric_9ff8f53204.jpg" alt="Waters SELECT SERIES Cyclic IMS: Mass spectrum highlighting resolution of >100,000 (FWHM) on the 7+ charge state of monomeric." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Mass_spectrum_highlighting_resolution_of_100_000_FWHM_on_the_7_charge_state_of_monomeric_9ff8f53204.jpg 234w," sizes="100vw" width="1024" height="682"></figure></div></div></div></div></div></div></div></div></div></div></div></div>

Waters SYNAPT XS High Resolution Mass Spectrometer

The SYNAPT XS Ion Mobility Time-of-Flight Mass Spectrometer provides ultimate flexibility, offering greater freedom of analytical choice to support scientific creativity and technical success for any application.

<div><div><h4><strong>Ultimate flexibility for deeper discovery</strong></h4></div></div><div><div><p><strong>In the arena of scientific discovery, the slow pace of advancement and escalating costs of research can prove to be a challenge. Unlike competitor systems with restricted inlet options, scan function limitations, or requiring multiple platforms, only Waters offers an all-encompassing high-performing LC-MS solution, the SYNAPT XS mass spectrometer, for ultimate flexibility and greater freedom of analytical choice – supporting scientific creativity and technical success for any application.</strong></p><ul><li><strong>Novel technology building blocks deliver cutting-edge analytical performance</strong></li><li><strong>SONAR</strong> and <strong>HDMSE</strong> provide a unique toolkit for interrogating complex mixtures</li><li><strong>Ion mobility</strong> multiplies peak capacity and selectivity of analysis</li><li><strong>CCS measurements</strong> increase security of compound identification</li><li><strong>Deeper discovery in Mass Spectrometry Imaging</strong> with<strong> </strong><a target="_blank" rel="noopener noreferrer" href="https://www.waters.com/waters/Full-Spectrum-Molecular-Imaging-/nav.htm?cid=135070661"><strong>Full Spectrum Molecular Imaging</strong></a> enabled by <a target="_blank" rel="noopener noreferrer" href="https://www.waters.com/waters/DESI-XS---Desorption-Electrospray-Ionization-/nav.htm?cid=135047466"><strong>DESI XS</strong></a> and MALDI</li></ul><h4><strong>Overview</strong></h4><div><div><div><div><ul><li><strong>Serve the broadest range of applications </strong>with the most extensive range of chromatograph inlets for ultimate flexibility</li><li><strong>Attain fragment ion information for every detectable component</strong> for unambiguous confirmation of compound identity with DIA modes <strong>SONAR</strong>, MSE, and <strong>HDMSE</strong></li><li><strong>Generate rich fragmentation data</strong> from highly complex samples in all acquisition modes including DDA</li><li>Simplify and streamline the mass spectral imaging workflow and deliver multi-layered, information-rich data with multiple imaging techniques and accompanying High Definition Imaging (HDI) Software</li><li><strong>Achieve automated higher order structure determination </strong>thorough confident identification, intact mass analysis, and best-in-class reproducibility</li><li><strong>Enhance MS/MS possibilities</strong> using complementary fragmentation techniques with high resolution and accurate mass measurements</li></ul></div></div><div><div><h5><strong>Recommended Use</strong></h5><p>For deeper discovery by aligning complimentary workflows on a single <strong>Ion mobility</strong> enabled time-of-flight mass spectrometer with the flexibility of multiple ion sources and acquisition modes.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_4_696d77ce2b.jpg" alt="Waters SYNAPT XS High Resolution Mass Spectrometer: The Waters SYNAPT XS offers flexibility and freedom of analytical choice with an extensive range of chromatographic inlets." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_4_696d77ce2b.jpg 234w," sizes="100vw" width="1024" height="682"></p><div><div><h3><strong>Cutting edge performance with novel technology</strong></h3><p>With technology building blocks inherited from the <strong>Waters Advanced Mass Spectrometry</strong> <strong>SELECT SERIES</strong>, advanced innovation is built-in, ensuring scientists using this platform are at the cutting edge of mass spectrometry while retaining the ease of use and established end-to-end workflows for which the <strong>SYNAPT </strong>is well known.</p><ul><li><strong>StepWave&nbsp;XS -&nbsp;</strong>Redesigned segmented quadrupole transfer optics provide enhanced sensitivity for challenging compounds while further improving levels of analytical robustness.</li><li><strong>Extended ToF -&nbsp;</strong>Delivers UPLC-compatible mass resolution, matrix-tolerant dynamic range, and quantitative results for the most complex samples, while offering superior specifications to previous SYNAPT models.</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_9f19abb382.jpg" alt="Waters SYNAPT XS High Resolution Mass Spectrometer: SYNAPT XS schematic." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_9f19abb382.jpg 245w," sizes="100vw" width="1024" height="546"></p></div></div><div><div><h3><strong>Interrogate complex mixtures with a unique toolkit</strong></h3><p>A complete analytical strategy requires the combination of appropriate complementary techniques to see the bigger picture. With both <strong>SONAR</strong> and IMS-based <strong>data independent acquisition</strong> (DIA) modes of operation on the SYNAPT XS, the discovery analyst is in a unique position to interrogate complex mixtures by complementary mechanisms. Both types of acquisition increase analytical <strong>peak capacity</strong>, providing ‘clean and clear’ fragmentation data, but based on different molecular properties. This provides a truly unique investigative toolbox for the in-depth interrogation of complex mixtures.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_2_9179e575a4.jpg" alt="Waters SYNAPT XS High Resolution Mass Spectrometer: During each scan the quadrupole separates co-eluting precursor masses by scanning the mass range, and transiting them in sequence. Fragment ions from different precursors can then be recorded separately and assigned with confidence." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_2_9179e575a4.jpg 245w," sizes="100vw" width="1024" height="593"></p></div></div><div><div><h3><strong>Discover more with ion mobility and CSS measurement</strong></h3><p>Conventional mass spectrometers separate components based on m/z. The SYNAPT XS also allows separation of molecules according to<strong> their size, shape, and charge during ion mobility experiments as a function of their collisional cross section</strong> (CCS). As well as ion mobility offering an additional dimension of resolution, multiplying <strong>peak capacity</strong>, and <strong>selectivity of analysis</strong> the measurement of CCS offers additional molecular identifiers. The measured CCS of an ion can be used to help confirm an ion’s identity or investigate its structure. The inclusion of ion mobility significantly increases the extent and confidence with which a scientist can profile complex mixtures and complex molecules – dramatically enhancing sample definition.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_3_2240bff527.jpg" alt="Waters SYNAPT XS High Resolution Mass Spectrometer: Retention and drift time principle ion mobility enabled data-independent LC-HDMSE analysis (LC-DIA-IM-MS)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_3_2240bff527.jpg 204w," sizes="100vw" width="1024" height="784"></p></div></div><div><div><h3><strong>Achieve ultra-confident structural characterization of components</strong></h3><p>Time aligned parallel (TAP) fragmentation is an acquisition mode unique to the T-Wave IMS design. It permits users to take the advantage of the <strong>TriWave configuration</strong>, which allows the pre-IMS T-Wave and post-IMS T-Wave to operate as two separate collision cells. The resultant CID-IMS-CID instrumental operation helps to provide ultra-confident structural characterization of components. <strong>TAP fragmentation</strong> provides a distinct advantage for building a complete structure, through superior fragment ion coverage, sensitivity, and accuracy compared to traditional MSⁿ or MS/MS techniques.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_5_4dd33f1ab5.jpg" alt="Waters SYNAPT XS High Resolution Mass Spectrometer: Schematic showing Time Aligned Parallel Fragmentation. " srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SYNAPT_XS_High_Resolution_Mass_Spectrometer_5_4dd33f1ab5.jpg 234w," sizes="100vw" width="1024" height="682"></p></div></div></div></div></div></div></div></div>

Waters BioAccord LC-MS System

The BioAccord LC-MS System enables routine biotherapeutic monitoring across development, manufacturing, and QC, with a compact design and user-friendly platform for non-MS experts.

<div><div id="title-61fa75209f" data-locator="title-with-text"><h3><strong>Routine biopharmaceutical analysis – accessible and accelerated</strong></h3></div></div><div><div id="text-73a19e9720" data-locator="text"><p><strong>Improving lab efficiency without sacrificing result quality is important but challenging. Now you can achieve high-quality biotherapeutic molecule data while maximizing efficiency with the ability to directly measure product attributes to assess product quality and process robustness.</strong></p><p><strong>The BioAccord LC-MS System</strong> is specifically designed for routine definition and monitoring of biotherapeutic attributes across biopharmaceutical process and product development, manufacturing, and QC, all within a small system footprint on a platform capable of operation by non-MS experts.&nbsp;</p><p>Analyze a broad range of product attributes using the intact molecule, subunits, peptide maps, and released glycans, all with greater sensitivity, selectivity, and dynamic range than traditional chromatographic and electrophoretic techniques.</p><ul><li>Make rapid, confident decisions with accessible, consistent high-quality data​</li><li>Ensure operational simplicity, result consistency, and lab productivity with workflow automation​</li><li>Compliant-ready platform that can be deployed and replicated from discovery through to QC.​</li><li>Achieve fast deployment, reliable operation, and a clear return on investment​</li></ul><h3><strong>Overview</strong></h3><ul><li>Compliant-ready platform ideal to deploy from discovery to quality control (QC)​</li><li>Achieve faster time to value, and consistent performance through automated set-up with SmartMS</li><li>Diagnose, and fix potential system issues before they affect data quality with intelligent health checks in SmartMS</li><li>Focus your team on what matters with a system that doesn't require LC-MS experts for routine operation</li><li>Make more informed, data-driven decisions with trustworthy LC-MS data directly available at the point of decision-making</li><li>Achieve the highest quality data in your lab, comparable to data previously available only from the complicated, and costly LC-MS systems used for product characterization</li></ul><p><strong>Recommended Use: </strong>For the rapid measurement of multiple product quality attributes during routine biopharmaceutical analysis.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_ACQUITY_R_Da_Detector_1_c570b28cc2/Waters-ACQUITY-RDa-Detector-1.jpeg" alt="Waters BioAccord LC-MS System" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_ACQUITY_R_Da_Detector_1_c570b28cc2/thumbnail_Waters-ACQUITY-RDa-Detector-1.jpeg 125w," sizes="100vw" width="1024" height="1274"></p><h3><strong>Accelerate decisions with less effort to collect and process high quality data</strong></h3><p>Minimize the time spent generating data and managing LC-MS performance and maximize time for actions driven by the high quality data generated with automated set-up and guided workflows.&nbsp;</p><h4><strong>Use the streamlined workflows with the BioAccord LC-MS System for:</strong></h4><ul><li>Intact mass analysis (proteins, subunits, oligonucleotides, mRNA fragments)</li><li>Peptide mapping and multi-attribute method (MAM)</li><li>Released N-glycan analysis</li><li>Oligonucleotide sequence confirmation</li><li>Impurity analysis for proteins, peptides, and oligonucleotides</li></ul><p>These workflows streamline method set-up, data acquisition and processing, and report generation to deliver the required information with minimal manual interventions.​ In addition to these core workflows, the BioAccord System also supports a range of other applications required in biotherapeutic process and product development, like cell culture media analysis, mRNA cap, and lipid nanoparticle analysis.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Bio_Accord_LC_MS_System_Visualize_your_data_with_intuitive_and_easy_to_review_layouts_9876dbe5a8.jpg" alt="Waters BioAccord LC-MS System: Visualize your data with intuitive and easy to review layouts. These results from a peptide MAM analysis show product quality attributes that are being monitored, flagging those that are out of specification." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Bio_Accord_LC_MS_System_Visualize_your_data_with_intuitive_and_easy_to_review_layouts_9876dbe5a8.jpg 245w," sizes="100vw" width="954" height="541"></p><h3><strong>Increase productivity by increasing data quality and reducing analysis failures</strong></h3><p>Non-specific adsorption of metal sensitive analytes can be unpredictable and challenging, leading to long system passivation times, large relative standard deviations (RSDs), and broad peaks that can be tough to detect and quantify.</p><p>The BioAccord LC-MS System incorporates ACQUITY Premier UPLC and Premier chemistries with MaxPeak High Performance Surfaces (HPS) Technology. These innovations maximize system readiness, decrease time to operation, and enable superior run-run and system-system consistency while improving sensitivity for the metal interacting analytes.&nbsp;</p><h4><strong>Through the application of MaxPeak HPS Technology, you can:</strong></h4><ul><li>Increase recovery and consistent detection of problematic peptides for enhanced peptide map and MAM analysis.</li><li>Achieve superior sensitivity and reproducibility for acidic glycans and lipids by minimizing analyte/surface interactions that lead to sample loss.</li><li>Save time and improve productivity by reducing or eliminating passivation for robust oligonucleotide analyses.</li><li>Minimize the risk of undetected peaks by minimizing metal-sensitive analyte loss, improving recovery and the lowering limits of detection.</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Bio_Accord_LC_MS_System_The_figure_A_shows_the_extracted_ion_chromatograms_XIC_for_GFYPSDIAVEWESNGQPENNYK_PENNYK_peptide_unmodified_and_deamidated_peptides_collected_for_a_NIS_Tm_Ab_digest_b14145461f.jpg" alt="Waters BioAccord LC-MS System: The figure (A) shows the extracted ion chromatograms (XIC) for GFYPSDIAVEWESNGQPENNYK (PENNYK) peptide unmodified and deamidated peptides collected for a NISTmAb digest. The chromatographic trace in solid line shows the XIC for PENNY peptides acquired on the BioAccord System. The inset shows all modification of PENNY peptide including succinimide modification. Figure (B) shows the total normalized peak area calculated for PENNY peptides using conventional and ACQUITY Premier UPLC system." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Bio_Accord_LC_MS_System_The_figure_A_shows_the_extracted_ion_chromatograms_XIC_for_GFYPSDIAVEWESNGQPENNYK_PENNYK_peptide_unmodified_and_deamidated_peptides_collected_for_a_NIS_Tm_Ab_digest_b14145461f.jpg 245w," sizes="100vw" width="1024" height="512"></p><h3><strong>Obtain quality data, faster than ever before</strong></h3><p>Quickly getting the quality data you need for your laboratory to stay productive is paramount but deploying traditional LC-MS systems is often rather slow. The integrated nature of the BioAccord LC-MS System means the system can be deployed easily and users can be productive faster through the delivery of system and applications training with appropriate biopharmaceutical methods, sample data, and system check standards for the common biopharmaceutical analysis workflows.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Bio_Accord_LC_MS_System_Mass_accuracy_summary_for_48_injections_that_representing_six_antibodies_with_eight_replicate_injections_each_ed012d8ad7.jpg" alt="Waters BioAccord LC-MS System: Mass accuracy summary for 48 injections that representing six antibodies with eight replicate injections each. Mass accuracy summary for 48 injections that representing six antibodies with eight replicate injections each." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Bio_Accord_LC_MS_System_Mass_accuracy_summary_for_48_injections_that_representing_six_antibodies_with_eight_replicate_injections_each_ed012d8ad7.jpg 245w," sizes="100vw" width="855" height="206"></p><h4><strong>With the BioAccord LC-MS System, you can:</strong></h4><ul><li>Ensure optimal system performance with biomolecule-based installation testing.</li><li>Enable users to quickly get up to speed with outcome-based application training.</li><li>Achieve high quality data with existing personnel or respond quickly to staff and project turnover challenges with reduced training burdens.</li></ul><h3><strong>Meeting your regulatory requirements, together</strong></h3><p>Meeting corporate and regulatory expectations for compliance and data integrity is critical to your laboratory operations, and those needs don’t change because LC-MS technology is moving into roles within manufacturing and quality control (QC) organizations.</p><p>Your data quality and compliance are our priority, too. The BioAccord System is built on the compliant-ready waters_connect informatics platform and backed by the long history at Waters of delivering compliant informatics and professional qualification services to streamline deployment.</p><h4><strong>With Waters, you’ll get:</strong></h4><ul><li>A single informatics platform based on a secure relational database architecture</li><li>Full audit trail for acquisition, processing, and reporting of data</li><li>Administrator-configurable roles and permissions</li><li>Network deployment of systems for maximum data safety and controlled accessibility</li><li>Characterization (Q-Tof) and routine analysis (BioAccord) systems on a common network for efficient system, data, and information management</li><li>Professional qualification services</li></ul></div></div>

Waters SELECT SERIES MRT mass spectrometer

Accelerate your research and comprehensively identify analytes in your complex samples with the SELECT SERIES MRT, built with state-of-the-art Multi Reflecting Time-of-Flight (MRT) technology. 

<div><div id="title-089dfa8549" data-locator="title-with-text"><h3><strong>Redefine performance with all the benefits of time-of-flight technology</strong></h3></div></div><div><div id="text-77997605f8" data-locator="text"><p><strong>Accelerate your research and comprehensively identify analytes in your complex samples with the SELECT SERIES MRT, built with state-of-the-art Multi Reflecting Time-of-Flight (MRT) technology. The SELECT SERIES MRT provides a unique combination of ultra-high resolution and specificity independent of scan speed, resulting in unambiguous compound identification with even the most complex samples.</strong></p><p>Distinguish the fine isotope structure of small molecules, resolve nominally isobaric interferences, and baseline resolve the isotopic envelope of multiply-charged ions with high resolution MRT technology. Unlike other high-resolution mass analyzers, SELECT SERIES MRT requires no compromise to your experiments, since mass resolution is consistent over a broad mass range and scan speeds.</p><h3><strong>Overview</strong></h3><div data-locator="section-container-body"><div><div><div data-locator="layoutcontainer-"><div><div id="text-b57ec45d49" data-locator="text"><ul><li>Confidently identify sample components with routine ppb mass accuracy&nbsp;</li><li>Resolve nominally isobaric interferences with high mass resolution, at all scan speeds</li><li>Reveal isotopic fine structure for unambiguous elemental compositions</li><li>Achieve high data quality in both MS and MS/MS</li><li>Simplify data archiving and rapidly process data with reduced data files sizes</li><li>Seamlessly interchange between MALDI, DESI XS and Electrospray sources for superior accuracy for compound identification</li></ul></div></div><div><div id="text-590eba5dee" data-locator="text"><h3><strong>Recommended Use</strong></h3><p>For unambiguous compound identification of even the most complex samples.</p><div><div id="text-d3d9e01296" data-locator="text"><h3 data-locator="modal-title"><strong>High resolution mass spectrometry, without compromise</strong></h3><p>The SELECT SERIES MRT achieves ground-breaking Time-of-Flight (ToF) resolution with the innovative use of multiple reflections of the ion beam between two gridless electrostatic mirrors in the mass analyzer. This extends the ions’ flight&nbsp;path, spatially refocusing the ion packets through a series of periodic lenses after each reflection maintaining sensitivity.&nbsp;Resolution Enhancement Mode (REM) extends the flight path by deflecting ions back for a second pass of the MRT analyzer increasing the resolving power by &gt;50% enabling &gt;300,000 FWHM.</p><figure class="image"><img style="aspect-ratio:1272/897;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_Schema_konstrukce_SELECT_SERIES_MRT_Q_Tof_systemu_a07ed0a724/Waters-Schema-konstrukce-SELECT-SERIES-MRT-QTof-systemu.jpg" alt="Waters SELECT SERIES MRT: instrument schematic." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_Schema_konstrukce_SELECT_SERIES_MRT_Q_Tof_systemu_a07ed0a724/thumbnail_Waters-Schema-konstrukce-SELECT-SERIES-MRT-QTof-systemu.jpg 221w," sizes="100vw" width="1272" height="897"></figure><p>The superior performance of the SELECT SERIES MRT results in high precision and routine part-per-billion mass accuracy independent of acquisition speed, providing unsurpassed quality of mass spectrometry data and information. The instrument is operated via the SELECT SERIES&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.waters.com/waters/nav.htm?cid=513164" data-di-id="di-id-e7513c98-b105e917">MassLynx</a>&nbsp;acquisition system with simple and intuitive experimental setup, acquisition, and processing of mass spectrometry data. It records data in the widely deployed Waters .raw file format, which you can easily access via the MassLynx API, export as (i)mzML, and other interchangeable data formats, ready to use in your data analysis strategy.</p><figure class="image"><img style="aspect-ratio:1024/682;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_MRT_REM_mode_fine_isotope_structure_for_caffeine_1443227594.jpg" alt="Waters SELECT SERIES MRT: REM mode fine isotope structure for caffeine." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_MRT_REM_mode_fine_isotope_structure_for_caffeine_1443227594.jpg 234w," sizes="100vw" width="1024" height="682"></figure><div><div id="text-78cca88bb7" data-locator="text"><h3 data-locator="modal-title"><strong>Redefining confidence for LC-MS</strong></h3><p>The SELECT SERIES MRT provides a new level of confidence for LC/MS experiments by routinely obtaining ppb mass accuracy, revealing fine isotope structure, all with the exceptional usability of a state-of-the-art Quadrupole Time-of-Flight (QToF). The spectacular performance enables search tolerances to be minimized, providing higher confidence in elemental composition and molecular formula assignments for known and unknown targets. Moreover, the ability to routinely access such high specificity from accurate mass for both precursor and product ions is truly transformative.</p><figure class="image"><img style="aspect-ratio:1024/570;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_MRT_Resolving_deamidations_for_confident_quantification_356c8f4783.jpg" alt="Waters SELECT SERIES MRT: Resolving deamidations for confident quantification. A) The deamidated forms of peptide HC:T23 elute in the tail of the native peptide peak. Without the ultra-high resolution of the SELECT SERIES MRT as shown in (B) identification and quantification of the deamidations." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_MRT_Resolving_deamidations_for_confident_quantification_356c8f4783.jpg 245w," sizes="100vw" width="1024" height="570"></figure><div><div id="text-1092d8da82" data-locator="text"><h3 data-locator="modal-title"><strong>Redefining clarity in mass spectrometry imaging</strong></h3><p>The SELECT SERIES MRT reduces analysis times by providing crystal clear, high-resolution images, acquired at fast imaging speeds without compromising mass spectral resolution or accuracy. This enables accelerated mass spectrometry imaging experiments while still resolving analytes from interferences, revealing fine structural information. The cutting-edge technology and intuitive software combine to revolutionize mass spectrometry imaging for a wide range of applications; where the ability to map compounds that differ by only a few mDa is changing the pace of research. This includes:</p><ul><li>Tissue analysis in biomedical research</li><li>Forensic research, including fingerprint analysis</li><li>Surface analysis, ranging from surface contamination analysis for semiconductor production, to analysis of tape stripped skin samples in the cosmetics industry</li></ul><div><div id="text-7f1b1e82f7" data-locator="text"><h3 data-locator="modal-title"><strong>Maximize MS imaging capabilities with DESI and MALDI</strong></h3><p>Maximize your mass spectrometry imaging capabilities and analytical flexibility with both DESI and MALDI on the SELECT SERIES MRT. Pair the SELECT SERIES MRT with <a target="_blank" rel="noopener noreferrer" href="https://www.waters.com/waters/nav.htm?cid=135047466" data-di-id="di-id-5d203d9f-b105e917">DESI XS</a>&nbsp;for high quality data and clear visualization of molecular spatial distributions. The speed and versatility of DESI imaging makes it best suited to the analysis of lipids and other small molecules under ambient, direct analysis conditions, without the need for additional matrices.</p><p>Use the high-performance MALDI source to improve imaging performance and ease-of-use, so you can rapidly image large tissue sections at high spatial resolution with improved selectivity and sensitivity. MALDI’s design uses a tightly focused laser beam profile, increasing signal-to-noise at high spatial resolutions and providing lateral resolution of 15 µm without oversampling, with data acquisition rates &gt;10 pixels per second, so scientists can acquire high intensity images quickly and efficiently. With MALDI and SELECT SERIES MRT, you can:</p><ul><li>Enable imaging of large sections with a full-sized Micro Titre Plate (MTP) format MALDI target plate</li><li>Access high spatial resolution through increased signal to noise (S/N), with a focused laser beam profile</li><li>Simplify usability with an automated isolation valve and laser focus control</li><li>Maximize productivity and uptime with easy cleaning and maintenance</li></ul><figure class="image"><img style="aspect-ratio:1349/1093;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Waters_SELECT_SERIES_MRT_2_8ead9924a6/Waters-SELECT-SERIES-MRT-2.jpg" alt="Waters SELECT SERIES MRT." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Waters_SELECT_SERIES_MRT_2_8ead9924a6/thumbnail_Waters-SELECT-SERIES-MRT-2.jpg 193w," sizes="100vw" width="1349" height="1093"></figure></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>

Products focused on LC/TOF - page 2

Related content

Aromatase Inhibitor Therapy Is Associated with Distinct Plasma Lipidomic Profiles in Postmenopausal Breast Cancer Patients

Science on the Front Lines: Cleanup of a Benzene Spill

The Future of Ion Chromatography | PFAS Testing, EPA 1621 & AOF Explained